Orris
attachment

ITP with Heavy menstrual bleeding on eltrambopag 55mg next management

Reading File
Finding Sources
Finding Sources
Searching PubMed

immune thrombocytopenia eltrombopag refractory management

Searching the Web

ITP eltrombopag inadequate response next line treatment heavy menstrual bleeding 2024 guidelines

Reading File
Reading File
Searching PubMed

immune thrombocytopenia refractory second line treatment

Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
I now have comprehensive data to provide a thorough answer. Here is the structured management plan:

Clinical Summary

Patient: 31-year-old female with ITP Current bloods (18 May 2026):
  • Platelets: 18 × 10⁹/L (critically low)
  • Hb: 7.7 g/dL (severe anaemia — likely from menstrual blood loss)
  • MCV 69.3 fL, MCH 21 pg, MCHC 303 g/L → microcytic hypochromic picture consistent with iron deficiency from chronic menorrhagia
  • WBC and differential: normal
  • HCT: 0.25
Current therapy: Eltrombopag — appears to be inadequate response (platelets still 18 × 10⁹/L)

Step 1: Immediate Priorities

A. Control Active Bleeding / HMB

InterventionRationale
Tranexamic acid 1 g TDS orallyAntifibrinolytic — reduces menstrual blood loss; safe in thrombocytopenia
Norethisterone 5 mg TDS or COCP (if no contraindication)Hormonal suppression of menstruation; can be used to stop bleeding acutely
Mirena IUD (when platelets are safer, >50 × 10⁹/L)Long-term menorrhagia control in ITP
IVIG 1 g/kg × 1–2 dosesRapid platelet rise (within 24–48 h) for acute haemorrhagic emergency
Hb of 7.7 with active bleeding: consider packed red cell transfusion if symptomatic (tachycardia, dyspnoea, haemodynamic instability)

B. Address Iron Deficiency

  • Start IV iron (preferred over oral given likely ongoing losses and severity): ferric carboxymaltose or iron sucrose
  • Oral iron acceptable if bleeding controlled

Step 2: Optimise / Escalate Platelet-Raising Therapy

Is eltrombopag at the right dose?

The standard starting dose is 50 mg/day, with dose escalation to a maximum of 75 mg/day if response is inadequate after 2–4 weeks. In East Asian patients, start at 25 mg and max is 75 mg.
Action: If on 50 mg (or 55 mg — note: standard doses are 25/50/75 mg; confirm the dose), escalate to 75 mg/day if not already at maximum.

Switch TPO-RA or combine:

If already at 75 mg with no response:
  • Switch to romiplostim (1–10 mcg/kg SC weekly) — different receptor binding domain; patients refractory to eltrombopag may respond
  • Avatrombopag (20 mg daily) is an alternative oral TPO-RA
TPO-RAs achieve platelet response in 70–90% of ITP patients, including those refractory to other treatments. — Goldman-Cecil Medicine, Harrison's 22e

Step 3: Add Second-Line Immunosuppressive Therapy

Since this patient has persistent severe thrombocytopenia on a TPO-RA, combination or alternative second-line therapy is warranted:

Option A: Rituximab (preferred if not yet used)

  • Dose: 375 mg/m² IV weekly × 4 doses
  • Response rate: ~40–60%; complete response ~25–40%
  • Combination with dexamethasone (40 mg × 4 days) improves response rate and duration
  • Allow 3–8 weeks for platelet response; bridge with steroids/IVIG

Option B: Dexamethasone pulse (if not recently tried)

  • 40 mg orally × 4 days, repeated every 2–4 weeks for 3–4 cycles
  • Sustained response in 29–42%

Option C: Fostamatinib (Syk kinase inhibitor)

  • For multi-refractory ITP (failed multiple prior lines)
  • 100 mg BD → escalate to 150 mg BD at 4 weeks if platelets remain <50 × 10⁹/L
  • Stable response in ~18% of heavily pretreated patients
  • Side effects: diarrhoea, hypertension, neutropenia
  • Washington Manual, Goldman-Cecil

Step 4: Consider Splenectomy (if medically appropriate)

  • Durable complete response in 65–70% of patients
  • Reserve after failure of at least 1–2 second-line agents
  • Pre-operative: Pneumococcal, meningococcal, and H. influenzae type B vaccination (ideally ≥2 weeks before surgery)
  • Cover platelet count pre-operatively with IVIG ± steroids

Step 5: Bridge and Rescue

ScenarioIntervention
Platelets <10 × 10⁹/L with active bleedingIVIG 1 g/kg + high-dose methylprednisolone 1 g IV + platelet transfusion (concurrent with IVIG)
Surgery required urgentlyIVIG + platelet transfusion to reach >50 × 10⁹/L

Summary Algorithm for This Patient

Current: ITP + Plt 18 × 10⁹/L + HMB + Hb 7.7 on eltrombopag
│
├─ 1. EMERGENT: Tranexamic acid + hormonal therapy for HMB
│         ± IVIG if severe/active bleeding
│         ± RBC transfusion (Hb 7.7, symptomatic)
│
├─ 2. HAEMATINIC: IV iron replacement
│
├─ 3. ESCALATE TPO-RA: Eltrombopag → 75 mg/day MAX
│         OR switch to romiplostim
│
├─ 4. ADD: Rituximab ± dexamethasone
│
├─ 5. IF REFRACTORY: Fostamatinib
│         OR other immunosuppressants (azathioprine, MMF, cyclosporine)
│
└─ 6. DEFINITIVE: Splenectomy (after vaccination)
References: Harrison's Principles of Internal Medicine 22e | Goldman-Cecil Medicine | Washington Manual of Medical Therapeutics | Mulholland & Greenfield's Surgery 7e
This is a shared conversation. Sign in to Orris to start your own chat.